- What We Do
- Get Involved
- Our Impact
- Our Events
- Boston Bakes for Breast Cancer
- Cape & Islands Bakes for Breast Cancer
- Rhode Island Bakes for Breast Cancer
- Cooking Classes
- Bake Sale
- Office Bake Sale
- Event Registration
- Contact Us
Tag Archives: Clinical Trials
A clinician and a scientist meet on the bridge that connects the research and patient-care buildings to discuss how a laboratory finding might benefit patients. A young woman, newly diagnosed with breast cancer, finds solace in a support program of her peers. A young investigator identifies molecular subtypes of ovarian cancer.
These are just a few of the powerful possibilities the Susan F. Smith Center for Women’s Cancers at Dana-Farber creates by bridging compassionate care and world-class basic and clinical research. This edition of Turning Point shares stories like these, and others. Innovators in Women’s Cancers Innovation occurs when experts in …
J. Dirk Iglehart, MD
By exploring the molecular workings of breast cancer and gynecologic cancers, researchers and clinicians at Dana-Farber Cancer Institute’s Susan F. Smith Center for Women’s Cancers (SSC) are gaining new insights into the many subtypes of these diseases. Under the leadership of J. Dirk Iglehart, MD, they are also studying how genetic similarities among different cancers can be exploited to develop more effective therapies.
The center’s many clinical trials – about 65 are currently open and a comprehensive list is available at www.dana-farber.org/ clinicaltrials – provide patients with the latest treatments and therapeutic developments. Many trials evaluate treatments prior …
Source: Dana-Farber Cancer Institute
Potential new drug target for hard-to-treat ‘triple-negative’ disease
Newswise — BOSTON—Scientists at Dana-Farber Cancer Institute have identified an overactive network of growth-spurring genes that drive stem-like breast cancer cells enriched in triple-negative breast tumors, a typically aggressive cancer that is highly resistant to current therapies.
Kornelia Polyak, MD, PhD, a breast cancer geneticist at Dana-Farber, and colleagues found that a large proportion of cells within these tumors showed elevated activity in a network of genes called the Jak2/Stat3 pathway. Experiments have demonstrated that a drug specifically aimed to block …